Scarica l'app Stockscreener
9.08
5.21%
0.45
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$8.63
Aprire:
$8.63
Volume 24 ore:
4.82M
Relative Volume:
1.91
Capitalizzazione di mercato:
$558.83M
Reddito:
$3.64M
Utile/perdita netta:
$-87.37M
Rapporto P/E:
-2.2092
EPS:
-4.11
Flusso di cassa netto:
$-86.46M
1 W Prestazione:
+10.46%
1M Prestazione:
+72.30%
6M Prestazione:
+59.86%
1 anno Prestazione:
+278.33%
Intervallo 1D:
$8.55
$9.40
Intervallo di 1 settimana:
$7.55
$9.40
Portata 52W:
$2.34
$9.40
Verastem Inc Stock (VSTM) Company Profile
Nome
Verastem Inc
Settore
Industria
Telefono
(781) 292-4200
Indirizzo
117 KENDRICK STREET, NEEDHAM, MA
Confronta VSTM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VSTM
Verastem Inc
|
9.08 | 490.52M | 3.64M | -87.37M | -86.46M | -4.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-10 | Iniziato | Jefferies | Buy |
| 2025-03-24 | Reiterato | H.C. Wainwright | Buy |
| 2024-12-31 | Reiterato | BTIG Research | Buy |
| 2024-09-30 | Iniziato | Guggenheim | Buy |
| 2023-11-21 | Ripresa | BTIG Research | Buy |
| 2023-09-27 | Iniziato | B. Riley Securities | Buy |
| 2023-06-15 | Aggiornamento | Mizuho | Neutral → Buy |
| 2022-09-07 | Ripresa | Alliance Global Partners | Buy |
| 2022-04-29 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-04-14 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-03-09 | Iniziato | Truist | Buy |
| 2021-07-01 | Iniziato | Alliance Global Partners | Buy |
| 2021-05-24 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2019-06-20 | Downgrade | BTIG Research | Buy → Neutral |
| 2019-05-10 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2018-07-13 | Iniziato | BTIG Research | Buy |
| 2018-05-02 | Iniziato | Seaport Global Securities | Buy |
| 2018-03-08 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-09-07 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-13 | Iniziato | Oppenheimer | Outperform |
| 2017-03-24 | Reiterato | H.C. Wainwright | Buy |
| 2015-09-29 | Downgrade | Cantor Fitzgerald | Buy → Hold |
| 2015-09-29 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2015-09-29 | Downgrade | Jefferies | Buy → Hold |
| 2015-09-29 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2015-09-28 | Downgrade | Mizuho | Buy → Neutral |
| 2015-09-28 | Downgrade | ROTH Capital | Buy → Neutral |
| 2015-09-09 | Iniziato | Raymond James | Strong Buy |
| 2015-05-12 | Reiterato | UBS | Buy |
| 2015-04-08 | Iniziato | H.C. Wainwright | Buy |
| 2015-01-23 | Reiterato | ROTH Capital | Buy |
| 2014-07-08 | Ripresa | Oppenheimer | Perform |
| 2014-02-11 | Iniziato | Mizuho | Buy |
Mostra tutto
Verastem Inc Borsa (VSTM) Ultime notizie
Verastem Advances with Phase 3 Trial Progress and Product Launch Boosting Prospects - MSN
Mizuho lowers Verastem stock price target to $14 on dilution from financing By Investing.com - Investing.com South Africa
Verastem Inc. Earnings Call: Positive Outlook with Key Achievements - MSN
Mizuho lowers Verastem stock price target to $14 on dilution from financing - Investing.com
Why Verastem Inc. stock attracts strong analyst attentionEarnings Recap Report & High Return Stock Watch Alerts - thegnnews.com
Verastem’s VS-7375 shows efficacy in lung cancer - MSN
Verastem Oncology's Breakthrough in KRAS-Driven Cancers and the High-Potential Launch of AVMAPKI FAKZYNJA CO-PACK - AInvest
Verastem price target lowered to $14 from $16 at Mizuho - MSN
Verastem Receives Buy Rating from Mizuho Securities with $14 Price Target - AInvest
Mizuho Securities Cuts Price Target on Verastem to $14 From $16, Maintains Outperform Rating - MarketScreener
Breakout Traders Target Verastem Inc. on Recovery SetupWeekly Market Outlook & Precise Swing Trade Entry Alerts - metal.it
Verastem shares rise 8.48% premarket after partner's trial data for GFH375 in lung cancer. - AInvest
Verastem stock rises as BTIG reiterates Buy rating on improved cancer drug data By Investing.com - Investing.com South Africa
Verastem stock rises as BTIG reiterates Buy rating on improved cancer drug data - Investing.com Australia
Verastem Soars 16.58% on Positive NSCLC Trial Data - AInvest
Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics’ Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer - BioSpace
Verastem Unveils Promising VS-7375 Study Results - TipRanks
Verastem stock soars after KRAS inhibitor shows strong lung cancer results By Investing.com - Investing.com South Africa
Verastem stock soars after KRAS inhibitor shows strong lung cancer results - Investing.com India
Verastem Oncology Announces Late-Breaking Abstract from Partner - GuruFocus
Verastem Oncology Announces Positive Efficacy Data for Partner GenFleet Therapeutics' KRAS G12D Inhibitor VS-7375 in Advanced Non-Small Cell Lung Cancer. - AInvest
New Lung Cancer Drug Achieves Breakthrough 69% Response Rate in Advanced NSCLC Patients - Stock Titan
Verastem, Inc. (NASDAQ:VSTM) Q2 2025 Earnings Call Transcript - Insider Monkey
Can Verastem Inc. stock double in the next yearReturn-Focused Stock Plans - thegnnews.com
Will Verastem’s Stock Keep Rising? - StocksToTrade
Verastem (VSTM.O) Surges 19.9% on KDJ Golden Cross and Mysterious Order Flow - AInvest
Verastem Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Verastem Seeks to Raise $300M through Mixed Securities Shelf - AInvest
Verastem's New Ovarian Cancer Drug Sees Strong Sales, Analysts Predict Significant Upside - AInvest
Verastem (VSTM.O) Surges 19.9%: What’s Behind the Sharp Intraday Move? - AInvest
Verastem's Q2 Earnings Exceed Expectations on Strong Ovarian Cancer Drug Sales - AInvest
Using Python tools to backtest Verastem Inc. strategiesAI Trend Detection for Entry Timing - Newser
What makes Verastem Inc. stock price move sharplyMassive ROI Stock Selections - thegnnews.com
Verastem's (VSTM) Breakthrough in KRAS-Driven Cancers and Commercialization Momentum - AInvest
Transcript : Verastem, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Verastem stock climbs on Q2 beat (VSTM:NASDAQ) - Seeking Alpha
Verastem’s Promising Phase 3 Study in Ovarian Cancer: A Potential Game-Changer? - TipRanks
RBC Raises Price Target on Verastem to $13 From $12, Keeps Outperform, Speculative Risk - MarketScreener
Verastem Inc files for mixed shelf offering of up to $300 millionSEC filing - MarketScreener
Earnings call transcript: Verastem Q2 2025 sees revenue growth and FDA approval - Investing.com
Verastem’s Promising Market Expansion and Financial Health Drive Buy Rating - TipRanks
Verastem: Q2 Earnings Snapshot - Connecticut Post
Verastem Q2 2025 Earnings Call Transcript - MarketBeat
Verastem Inc (VSTM) Q2 2025 Earnings Call Highlights: FDA Approval and Strong Launch Drive ... By GuruFocus - Investing.com Canada
Verastem Oncology’s Q2 2025 Financial and Business Highlights - TipRanks
Verastem Inc (VSTM) Q2 2025 Earnings Call Highlights: FDA Approval and Strong Launch Drive Positive Momentum - GuruFocus
Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates - BioSpace
Verastem 2025 Q2 Earnings Deepened Losses Amid Product Launch - AInvest
Verastem Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Custom strategy builders for tracking Verastem Inc.Free Short Term Buy List With Stop Protection - Newser
Verastem Oncology Gambles On Cancer Drug Launch Despite Deepening Losses - Finimize
Verastem Inc Azioni (VSTM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Verastem Inc Azioni (VSTM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Paterson Dan | President and CEO |
Jun 20 '25 |
Sale |
5.13 |
17,808 |
91,355 |
443,839 |
| Calkins Daniel | Chief Financial Officer |
Jun 20 '25 |
Sale |
5.13 |
4,110 |
21,084 |
109,945 |
| Calkins Daniel | Chief Financial Officer |
Jun 23 '25 |
Sale |
4.71 |
25 |
118 |
109,920 |
0.94%
1.72%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):